AR035006A1 - Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. - Google Patents

Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.

Info

Publication number
AR035006A1
AR035006A1 ARP990106128A ARP990106128A AR035006A1 AR 035006 A1 AR035006 A1 AR 035006A1 AR P990106128 A ARP990106128 A AR P990106128A AR P990106128 A ARP990106128 A AR P990106128A AR 035006 A1 AR035006 A1 AR 035006A1
Authority
AR
Argentina
Prior art keywords
derivative
dibenzo
manufacture
pharmaceutical composition
ciclohepteno
Prior art date
Application number
ARP990106128A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR035006A1 publication Critical patent/AR035006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe derivado de naftiridin-dibenzo[a,d] cicloheptano-10-acético que comprende un compuesto de la fórmula (1) que es un agente antagonista del receptor de vitronectina y es útil para el tratamiento de la osteoporosis, o una sal farmacéuticamente aceptable de éste, una composición farmacéutica y el uso de los mismos para la fabricación de un medicamento antagonista del receptor de vitronectina.
ARP990106128A 1998-12-04 1999-12-02 Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. AR035006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
AR035006A1 true AR035006A1 (es) 2004-04-14

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106128A AR035006A1 (es) 1998-12-04 1999-12-02 Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.

Country Status (39)

Country Link
US (1) US6495560B1 (es)
EP (1) EP1146874B1 (es)
JP (1) JP4481504B2 (es)
KR (1) KR100620485B1 (es)
CN (1) CN1147300C (es)
AP (1) AP1534A (es)
AR (1) AR035006A1 (es)
AT (1) ATE277043T1 (es)
AU (1) AU754408B2 (es)
BG (1) BG65118B1 (es)
BR (1) BR9915879A (es)
CA (1) CA2353415A1 (es)
CO (1) CO5150166A1 (es)
CZ (1) CZ20011963A3 (es)
DE (1) DE69920518T2 (es)
DK (1) DK1146874T3 (es)
DZ (1) DZ2954A1 (es)
EA (1) EA003254B1 (es)
EG (1) EG24025A (es)
ES (1) ES2229798T3 (es)
HK (1) HK1042037B (es)
HU (1) HUP0104804A3 (es)
ID (1) ID28811A (es)
IL (2) IL143390A0 (es)
MA (1) MA25265A1 (es)
NO (1) NO318895B1 (es)
NZ (1) NZ511876A (es)
OA (1) OA11724A (es)
PE (1) PE20001563A1 (es)
PL (1) PL195973B1 (es)
PT (1) PT1146874E (es)
SI (1) SI1146874T1 (es)
SK (1) SK7452001A3 (es)
TR (1) TR200101654T2 (es)
TW (1) TW482673B (es)
UA (1) UA71586C2 (es)
UY (1) UY25824A1 (es)
WO (1) WO2000033838A1 (es)
ZA (1) ZA200104398B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269821A1 (en) * 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
DE60118025T2 (de) * 2000-10-24 2006-11-23 Merck & Co., Inc. Dibenzoxazepin-alpha-v-integrin-rezeptorantagonist
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
US6872730B2 (en) * 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006516144A (ja) 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
AR052823A1 (es) * 2004-12-21 2007-04-04 Smithkline Beecham Corp Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
SI3050878T1 (sl) 2013-09-24 2022-01-31 Fujifilm Corporation Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
WO1998013278A1 (de) * 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
CA2353415A1 (en) 2000-06-15
CN1334730A (zh) 2002-02-06
PT1146874E (pt) 2005-02-28
CZ20011963A3 (cs) 2001-11-14
MA25265A1 (fr) 2001-10-01
EG24025A (en) 2008-03-26
UY25824A1 (es) 2001-07-31
JP2003523931A (ja) 2003-08-12
SK7452001A3 (en) 2001-12-03
PL348702A1 (en) 2002-06-03
AU1750200A (en) 2000-06-26
TR200101654T2 (tr) 2002-03-21
DE69920518D1 (de) 2004-10-28
ZA200104398B (en) 2002-05-29
KR100620485B1 (ko) 2006-09-13
SI1146874T1 (en) 2005-04-30
UA71586C2 (en) 2004-12-15
NO20012732D0 (no) 2001-06-01
OA11724A (en) 2005-01-26
IL143390A0 (en) 2002-04-21
BG105651A (en) 2002-02-28
CN1147300C (zh) 2004-04-28
DZ2954A1 (fr) 2004-06-20
ID28811A (id) 2001-07-05
ATE277043T1 (de) 2004-10-15
PL195973B1 (pl) 2007-11-30
EP1146874A4 (en) 2002-06-05
HUP0104804A3 (en) 2002-12-28
CO5150166A1 (es) 2002-04-29
PE20001563A1 (es) 2001-02-09
EP1146874A1 (en) 2001-10-24
TW482673B (en) 2002-04-11
AU754408B2 (en) 2002-11-14
IL143390A (en) 2006-07-05
HK1042037A1 (en) 2002-08-02
AP1534A (en) 2006-01-09
JP4481504B2 (ja) 2010-06-16
NO318895B1 (no) 2005-05-18
EP1146874B1 (en) 2004-09-22
US6495560B1 (en) 2002-12-17
WO2000033838A1 (en) 2000-06-15
DK1146874T3 (da) 2005-01-31
BR9915879A (pt) 2002-02-13
KR20010080669A (ko) 2001-08-22
NZ511876A (en) 2004-02-27
ES2229798T3 (es) 2005-04-16
EA003254B1 (ru) 2003-02-27
HK1042037B (en) 2005-07-29
NO20012732L (no) 2001-08-01
BG65118B1 (bg) 2007-03-30
HUP0104804A2 (hu) 2002-05-29
EA200100618A1 (ru) 2001-12-24
DE69920518T2 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
AR035348A1 (es) Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR029403A1 (es) Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AR029320A1 (es) Acidos aril carboxilicos y derivados de tetrazol, un proceso para su fabricacion, una composicion farmaceutica y el uso de los mismos para la produccion de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure